Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Daisuke Hashimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7880-889X; OpenAlex author ID A5045459990, A5121982623. Sources: OpenAlex.

Their work

Papers
57 (first author 15, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
182
Papers, trials and grants by year

2014: 3 papers · 2015: 1 paper · 2016: 4 papers · 2017: 3 papers · 2018: 6 papers · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 6 papers · 2023: 8 papers · 2024: 4 papers · 2025: 9 papers · 2026: 8 papers

Papers 50 of 57

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… First author DOI 10.1002/jhbp.70054↗
  3. Survival Impact of Pathological Residual Patterns for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1002/jhbp.70146↗
  4. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  5. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  6. Fecal Bifidobacterium Serves as a Predictor of Postoperative Recurrence After Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2025.100779↗
  7. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  8. Multi-hole Versus Fully Covered Self-expandable Metal Stents for Distal Biliary Obstruction in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002722↗
  9. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  10. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  11. Long-term outcomes of prophylactic right-half dissection of the superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic ductal adenocar… First author DOI 10.1007/s00595-025-03062-6↗
  12. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  13. Author's reply to the Letter to Editor regarding "Exploring the Role of Neoadjuvant Therapy for Resectable Pancreatic Cancer". First author DOI 10.1016/j.pan.2024.11.017↗
  14. Defining oligo-recurrence criteria for locoregional intervention in pancreatic ductal adenocarcinoma: A multidisciplinary era perspective. First author DOI 10.1016/j.pan.2025.08.020↗
  15. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  16. Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-024-16361-y↗
  17. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  18. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  19. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clini… First author DOI 10.1016/j.pan.2024.03.012↗
  20. Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal … Co-author DOI 10.1016/j.pan.2024.06.001↗
  21. Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib. First author DOI 10.1186/s40792-024-01975-x↗
  22. Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail. First author DOI 10.1002/ags3.12608↗
  23. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  24. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal aden… Co-author DOI 10.1016/j.pan.2022.11.012↗
  25. Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2023.04.001↗
  26. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  27. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  28. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospectiv… Co-author DOI 10.21037/jgo-23-655↗
  29. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12103477↗
  30. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1026↗
  31. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  32. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  33. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  34. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Co-author DOI 10.3390/cancers14051354↗
  35. Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, Radiological and NAT Regimen Prognostic Factors-Literature Review. First author DOI 10.3390/medicina58060756↗
  36. Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therap… Co-author DOI 10.1007/s00595-021-02308-3↗
  37. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗
  38. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  39. Efficacy of Staging Laparoscopy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14037↗
  40. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. Co-author DOI 10.1007/s00535-018-01535-9↗
  41. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2017.08.016↗
  42. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Unde… Co-author DOI 10.1097/mpa.0000000000001146↗
  43. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Co-author DOI 10.1111/cas.13467↗
  44. Multiple Primary Cancers in Patients with Pancreatic Cancer. First author DOI 10.1177/000313481808401205↗
  45. Thoracic wall muscle metastasis from pancreatic cancer. First author DOI 10.1186/s40792-017-0393-0↗
  46. Cystic gastric metastasis from pancreatic cancer. First author DOI 10.1186/s40792-018-0443-2↗
  47. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  48. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Co-author DOI 10.1097/mpa.0000000000000897↗
  49. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-5799-1↗
  50. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. First author DOI 10.1007/s00595-015-1238-8↗

Closest collaborators

The 25 strongest of 182 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 32 shared papers, 2021–2026 · strength 5.89
  2. So Yamaki · 25 shared papers, 2021–2026 · strength 4.40
  3. Tomohisa Yamamoto · 16 shared papers, 2021–2025 · strength 2.34
  4. Tsukasa Ikeura · 12 shared papers, 2022–2026 · strength 2.19
  5. Mitsugu Sekimoto · 13 shared papers, 2021–2025 · strength 1.99
  6. Yuki Matsui · 8 shared papers, 2022–2026 · strength 1.63
  7. Tsutomu Fujii · 9 shared papers, 2021–2026 · strength 1.33
  8. Michiaki Unno · 7 shared papers, 2022–2026 · strength 1.26
  9. Masamichi Mizuma · 6 shared papers, 2025–2026 · strength 1.19
  10. Kenichiro Uemura · 7 shared papers, 2022–2026 · strength 1.18
  11. Satoshi Hirano · 7 shared papers, 2021–2026 · strength 1.14
  12. Hidetaka Miyazaki · 5 shared papers, 2024–2026 · strength 1.12
  13. Koh Nakamaru · 6 shared papers, 2022–2026 · strength 1.11
  14. Atsushi Oba · 6 shared papers, 2023–2026 · strength 1.02
  15. Akira Chikamoto · 16 shared papers, 2014–2019 · strength 1.01
  16. Suguru Yamada · 5 shared papers, 2021–2025 · strength 1.00
  17. Fuyuhiko Motoi · 6 shared papers, 2021–2026 · strength 0.99
  18. Takashi Ito · 5 shared papers, 2023–2026 · strength 0.97
  19. Makoto Naganuma · 5 shared papers, 2023–2026 · strength 0.97
  20. Yosuke Inoue · 5 shared papers, 2023–2026 · strength 0.88
  21. Yoshifumi Takeyama · 5 shared papers, 2023–2026 · strength 0.82
  22. Denys Tsybulskyi · 4 shared papers, 2023–2026 · strength 0.81
  23. Kenjiro Okada · 4 shared papers, 2025–2026 · strength 0.78
  24. Masashi Kanai · 3 shared papers, 2025–2026 · strength 0.74
  25. Nobuhiko Nakagawa · 3 shared papers, 2025–2026 · strength 0.65

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.